<DOC>
	<DOCNO>NCT02156791</DOCNO>
	<brief_summary>gpASIT+TM product base highly purified allergen fragment obtain grass pollen . The purpose clinical trial confirm safety , clinical tolerability immunogenicity increase dos gpASIT+TM administer subcutaneously patient grass pollen-induced allergic rhinoconjunctivitis , determine maximal tolerate dose gpASIT+TM .</brief_summary>
	<brief_title>Safety , Clinical Tolerability Immunogenicity Increasing Doses gpASIT+TM</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Signed date Informed Consent Form legally competent patient Female male patient age 1870 year The patient good physical mental health accord his/her medical history vital sign Nonpregnant , nonlactating female adequate contraception Females unable bear child must sign form adequate contraceptive protection ( i.e . tubule ligation , hysterectomy , postmenopausal ( define minimum one year since last menstrual period ) ) Allergy diagnosis : A medical history moderate severe seasonal allergic rhinoconjunctivitis ( SAR ) grass pollen season least two previous year A positive skin prick test ( wheal diameter ≥ 3 mm ) grasspollen mixture , histamine wheal ≥ 3 mm , NaCl control reaction ≤ 2 mm Specific IgE grass pollen ( IgE &gt; 0.7 kU/l ) Patients treat antiallergic medication least 2 year prior enrolment In asthmatic patient : Confirmed diagnosis control asthma accord GINAguidelines ( GINA 2011 ) Simultaneous participation clinical trial previous participation within 30 day inclusion Previous immunotherapy grass allergens within last 5 year Ongoing immunotherapy Patients relationship dependence Sponsor and/ Investigator Inability understand instructions/ study document Patients history hypersensitivity excipients investigational product Patients partly control uncontrolled asthma Chronic asthma emphysema , particularly FEV 1 &lt; 80 % predict value ( ECSC ) Patients symptomatic perennial inhalant allergens subject regularly expose Patients history ragweed allergy Patients history renal disease chronic hepatic disease Patients malignant disease Patients know severe autoimmune disease patient positive test ANA , ANCA ASCA Patients chronic disease may impair patient 's ability participate trial ( i.e . severe congestive heart failure , active gastric ulcer , inflammatory bowel disease , uncontrolled diabetes mellitus , etc… ) Patients require betablockers/ACEinhibitors medication Patients require antiIgE antibody , mast cell stabilizer , antileukotriene agent Patients contraindication use adrenaline Patients febrile illness ( &gt; 37.5°C , oral ) Patients know positive serology HIV1/2 , HBV HCV Patients immunocompromised medication illness , receive vaccine corticoid immunosuppressive medication within 1 month trial entry Female patient pregnant , lactating , childbearing potential protected pregnancy sufficiently reliable method Consumption corticoid ( oral , topic nasal ) antihistaminic drug within 3 week precede trial ( screen visit ) Patients laboratory value great grade 1 accord FDA Guidance Industry preventive Vaccine Trials ( FDA 2007 ) Unreliable patient include noncompliant patient , patient know alcoholism drug abuse history serious psychiatric disorder well patient unwilling give inform consent abide requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Seasonal allergic rhinoconjunctivitis</keyword>
	<keyword>Grass pollen</keyword>
	<keyword>Allergen specific immunotherapy</keyword>
</DOC>